⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
RYTM News
Rhythm Pharmaceuticals, Inc. Common Stock
Rhythm Pharmaceuticals Announces Participation in Upcoming Guggenheim Biotech Summit
globenewswire.com
RYTM
Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Product Revenues and Upcoming Milestones
globenewswire.com
RYTM
Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome
globenewswire.com
RYTM
Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome
globenewswire.com
RYTM
Rhythm Pharmaceuticals Announces Presentation of Four Datasets at ObesityWeek® 2025
globenewswire.com
RYTM
Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity
globenewswire.com
RYTM
Rhythm Pharmaceuticals Announces Public Reimbursement for IMCIVREE® (setmelanotide) in Canada in Five Provinces and Under the Federal Non-Insured Health Benefits Program
globenewswire.com
RYTM
Rhythm Pharmaceuticals annonce le remboursement public de l'IMCIVREE® (setmélanotide) au Canada dans cinq provinces et dans le cadre du Programme fédéral des services de santé non assurés
globenewswire.com
RYTM
Rhythm Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Update
globenewswire.com
RYTM